Patents by Inventor Stanley B. Prusiner

Stanley B. Prusiner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9658213
    Abstract: An entire complement or plurality of isotopically labeled amino acids are introduced into the diet of a test subject. Sufficient amounts of the isotopically labeled amino acids are provided to the subject in order to ensure that the subject incorporates a large percentage of isotopically labeled amino acids into newly synthesized proteins. Tissue samples are removed from the subject at different points in time and proteins are extracted and separated so that different proteins of different tissues can be individually analyzed and their amount and pattern of isotopic labeling can be determined. In a preferred embodiment, the methodology can be combined with proteolytic digestion to peptides and analysis by mass spectrometry in order to measure rates of protein turnover in vivo relating to thousands of different proteins.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: May 23, 2017
    Assignee: The Regents of the University of California
    Inventors: Stanley B. Prusiner, John C. Price, Sina Ghaemmaghami, Al Burlingame, Shenheng Guan
  • Publication number: 20140329863
    Abstract: Described herein are novel compositions and methods of treatment addressing diseases such as neurodegenerative diseases, including prion diseases and Alzheimer's disease.
    Type: Application
    Filed: February 26, 2014
    Publication date: November 6, 2014
    Applicant: The Regents of the University of California
    Inventors: Adam R. Renslo, Alejandra Gallardo-Godoy, Michael B. Silber, Stanley B. Prusiner, Kurt Giles, Zhe Li, R. Jeffrey Neitz
  • Publication number: 20140287957
    Abstract: An entire complement or plurality of isotopically labeled amino acids are introduced into the diet of a test subject. Sufficient amounts of the isotopically labeled amino acids are provided to the subject in order to ensure that the subject incorporates a large percentage of isotopically labeled amino acids into newly synthesized proteins. Tissue samples are removed from the subject at different points in time and proteins are extracted and separated so that different proteins of different tissues can be individually analyzed and their amount and pattern of isotopic labeling can be determined. In a preferred embodiment, the methodology can be combined with proteolytic digestion to peptides and analysis by mass spectrometry in order to measure rates of protein turnover in vivo relating to thousands of different proteins.
    Type: Application
    Filed: June 17, 2011
    Publication date: September 25, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Stanley B. Prusiner, John C. Price, Sina Ghaemmaghami, Al Burlingame, Shenheng Guan
  • Publication number: 20120009209
    Abstract: Peptide sequences that specifically bind infectious prion protein for the generation of antibodies and therapeutic agents are disclosed herein.
    Type: Application
    Filed: June 9, 2011
    Publication date: January 12, 2012
    Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, The United States of America as represented by the Secretary of Agriculture
    Inventors: Robert M. Hnasko, Larry H. Stanker, Stanley B. Prusiner
  • Patent number: 7307103
    Abstract: An antiseptic composition useful in destroying the infectivity of infectious proteins such as prions is disclosed. The antiseptic composition is preferably maintained at either a low pH of 4.0 or less or a high pH of 10.0 or more either of which allows for an environment under which the active component (which is preferably sodium dodecyl sulfate) destroys infectivity. The composition may be added to blood, blood products, collagen, tissues and organs prior to transplantation. The composition also may be added to livestock feed to denature any prions in the livestock. Methods of denaturing infectious proteins are also disclosed which method can use but do not require higher temperatures and long period of exposure.
    Type: Grant
    Filed: August 14, 2003
    Date of Patent: December 11, 2007
    Assignee: The Regents of the University of California
    Inventors: Stanley B. Prusiner, Surachai Supattapone
  • Patent number: 7226609
    Abstract: An antiseptic composition useful in destroying the infectivity of infectious proteins such as prions is disclosed. The antiseptic composition is preferably maintained at either a low pH of 4.0 or less or a high pH of 10.0 or more either of which allows for an environment under which the active component (which is preferably sodium dodecyl sulfate) destroys infectivity. The composition may be added to blood, blood products, collagen, tissues and organs prior to transplantation. The composition also may be added to livestock feed to denature any prions in the livestock. Methods of denaturing infectious proteins are also disclosed which method can use but do not require higher temperatures and long period of exposure.
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: June 5, 2007
    Assignee: The Regents of the University of California
    Inventors: Stanley B. Prusiner, Surachai Supattapone
  • Patent number: 7166477
    Abstract: A method of preparing a sample of muscle tissue and of assaying the prepared sample to determine the presence of prions in the sample is disclosed. The muscle tissue is homogenized and mixed with a complexing agent which forms a complex with a higher specific gravity than PrPSc, the complexing agent or other components of the homogenate. Gravity is then used (e.g. ultra centrifugation) to concentrate the complex and the concentrate is assayed to detect prions. The muscle tissue is preferably extracted from a muscle or group of muscles such as hind limb muscle which have a higher or more preferably the highest concentration of prions as compared to other muscle in the mammal.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: January 23, 2007
    Assignee: The Regents of the University of California
    Inventors: Stanley B. Prusiner, Patrick Bosque
  • Patent number: 7163806
    Abstract: The present invention comprises a method for producing mammalian therapeutics free from prion contamination and cells for use in such methods. Such therapeutics are produced in somatic cells having a genome with an artificially altered PrP gene. The PrP gene in these cells may be ablated, or replaced by an exogenous inducible form of the PrP gene. The endogenous gene in the host cells may be disrupted, or disrupted and replaced by an exogenous PrP gene.
    Type: Grant
    Filed: February 6, 2004
    Date of Patent: January 16, 2007
    Assignee: The Regents of the University of California
    Inventor: Stanley B. Prusiner
  • Patent number: 7163798
    Abstract: An assay method is disclosed which isolates and detects the presence of a disease related conformation of a protein (e.g., PrPSc) present in a sample also containing the non-disease related conformation of the protein (e.g., PrPC). The sample is treated (e.g., contacted with protease) in a manner which hydrolyzes the disease related conformation and not the non-disease related conformation. The treated sample is contacted with a binding partner (e.g., a labeled antibody which binds PrPSc) and the occurrence of binding provides and indication that PrPSc is present. Alternatively the PrPSc of the treated sample is denatured (e.g., contacted with guanadine) or unfolded. The unfolded PrPSc is contacted with a binding partner and the occurrence of binding indicates the presence of PrPSc in the sample.
    Type: Grant
    Filed: March 3, 2006
    Date of Patent: January 16, 2007
    Assignee: The Regents of the University of California
    Inventors: Stanley B. Prusiner, Jiri G. Safar
  • Patent number: 7151000
    Abstract: A sample is prepared from blood in a manner which makes it possible to further analyze proteins in the sample, e.g. to detect prions in the sample. Blood is extracted, allowed to clot and subjected to separation processing (e.g. centrifugation) to obtain serum. The serum is treated with a complexing agent which agent binds prions in the sample forming an agent/protein complex which makes it possible to concentrate the complex. Concentration of the complex results in a sample which can be successfully analyzed, e.g. assayed using a range of different types of assay methodologies for detecting prions.
    Type: Grant
    Filed: April 28, 2003
    Date of Patent: December 19, 2006
    Assignee: The Regents of the University of California
    Inventors: Stanley B. Prusiner, Jiri G. Safar
  • Patent number: 7094553
    Abstract: The present invention provides antibodies that specifically bind with a high degree of binding affinity to a native ungulate PrPC and/or a denatured ungulate PrPSc, but not to a native ungulate PrPSc. Preferred antibodies find native bovine PrPC and treated PrPSc but not native bovine PrPSc and can be used in an assay to determine if a sample is infected with infectious prions, i.e. PrPSc.
    Type: Grant
    Filed: January 30, 2003
    Date of Patent: August 22, 2006
    Assignees: The Regents of the University of California, The Scripps Research Institute
    Inventors: Stanley B. Prusiner, Jiri G. Safar, R. Anthony Williamson, Dennis R. Burton
  • Patent number: 7087213
    Abstract: A method of isolating and detecting the presence of a disease related conformation of a protein (e.g., PrPSc) is disclosed. The sample is treated such as by contacting it with a protease and then contacting the treated sample with a binding partner which binds the PrPSc which can be isolated and separated from the sample.
    Type: Grant
    Filed: February 8, 2005
    Date of Patent: August 8, 2006
    Assignee: The Regents of the University of California
    Inventors: Stanley B. Prusiner, Jiri G. Safar
  • Patent number: 7052675
    Abstract: Antibodies are disclosed which specifically bind to native PrPSc in situ. Preferred antibodies bind only to the native PrPSc of a particular species e.g., human, cow, sheep, pig, etc. Particularly preferred antibodies bind specifically to a particular isoform of human PrPSc. Preferred antibodies of the invention are (1) produced by phage display methodology, (2) bind specifically to native PrPSc, (3) neutralizes the infectivity of prions, (4) bind to PrPSc in situ and (5) bind 50% or more of PrPSc in a liquid flowable sample. Antibodies of the invention can be bound to a substrate and used to assay a sample (which has any PrPc denatured via proteinase K) for the presence of PrPSc of a specific species which PrPSc is associated with disease. Antibodies which specifically bind to human PrPSc can be labeled and injected carrying out an in vivo diagnostic test to determine if the human is infected with prions associated with disease.
    Type: Grant
    Filed: December 29, 2004
    Date of Patent: May 30, 2006
    Assignees: The Regents of the University of California, The Scripps Research Institute
    Inventors: Stanley B. Prusiner, R. Anthony Williamson, Dennis R. Burton
  • Patent number: 6962975
    Abstract: The invention provides prion protein standards for use as reference materials for prion detection. The standard may be species specific, i.e. the standard is comprised of a preparation for detection of a single strain prion or it may be prepared to allow detection of multiple prion strains simultaneously. The invention also provides methods of preparing the prion protein standards using a group of non-human host mammals which have their genome manipulated with respect to genetic material related to a PrP gene such that the mammals are susceptible to infection with a prion which generally only infects an animal which is genetically diverse from the host.
    Type: Grant
    Filed: November 17, 1999
    Date of Patent: November 8, 2005
    Assignee: The Regents of the University of California
    Inventor: Stanley B. Prusiner
  • Patent number: 6916419
    Abstract: Devices such as flow through columns, substrates such as spherical polymer beads, and methods of using such to remove prions from any liquid sample are disclosed. A surface of a substrate is coated with a prion complexing agent, such as a salt of phosphotungstic acid. Blood or plasma passing through a column containing beads coated with prion complexing agent are rendered prion free.
    Type: Grant
    Filed: March 21, 2003
    Date of Patent: July 12, 2005
    Assignee: The Regents of the University of California
    Inventors: Stanley B. Prusiner, Jiri G. Safar
  • Patent number: 6875577
    Abstract: An assay method is disclosed which isolates and detects the presence of a disease related conformation of a protein (e.g., PrPSc) present in a sample also containing the non-disease related conformation of the protein (e.g., PrPC). The sample is treated (e.g., contacted with protease) in a manner which hydrolyzes the disease related conformation and not the non-disease related conformation. The treated sample is contacted with a binding partner (e.g., a labeled antibody which binds PrPSc) and the occurrence of binding provides and indication that PrPSc is present. Alternatively the PrPSc of the treated sample is denatured (e.g., contacted with guanadine) or unfolded. The unfolded PrPSc is contacted with a binding partner and the occurrence of binding indicates the presence of PrPSc in the sample.
    Type: Grant
    Filed: December 18, 2003
    Date of Patent: April 5, 2005
    Assignee: The Regents of the University of California
    Inventors: Stanley B. Prusiner, Jiri G. Safar
  • Patent number: 6858397
    Abstract: Antibodies are disclosed which specifically bind to native PrPSc in situ. Preferred antibodies bind only to the native PrPSc of a particular species e.g., human, cow, sheep, pig, etc. Particularly preferred antibodies bind specifically to a particular isoform of human PrPSc. Preferred antibodies of the invention are (1) produced by phage display methodology, (2) bind specifically to native PrPSc, (3) neutralizes the infectivity of prions, (4) bind to PrPSc in situ and (5) bind 50% or more of PrPSc in a liquid flowable sample. Antibodies of the invention can be bound to a substrate and used to assay a sample (which has any PrPc denatured via proteinase K) for the presence of PrPSc of a specific species which PrPSc is associated with disease. Antibodies which specifically bind to human PrPSc can be labeled and injected carrying out an in vivo diagnostic test to determine if the human is infected with prions associated with disease.
    Type: Grant
    Filed: May 9, 2003
    Date of Patent: February 22, 2005
    Assignees: The Regents of the University of California, The Scripps Research Institute
    Inventors: Stanley B. Prusiner, R. Anthony Williamson, Dennis R. Burton
  • Publication number: 20040229898
    Abstract: The invention is drawn to compositions and methods for inhibiting and treating malformed forms of proteins causing neurodegenerative disease, such as protease resistant prion proteins (PrPSc) and those associated with transmissible spongiform encephalopathies (TSEs). Bis-acridines are characterized by a dimeric motif, comprising two acridine heterocycles tethered by a linker. A library of bis-(6-chloro-2-methoxy-acridin-9-yl) and bis-(7-chloro-2-methoxy-benzo[b][1,5]naphthyridin-10-yl) analogs were synthesized to explore the effect of structurally diverse linkers on PrPSc replication in ScN2a cells. Structure-activity analysis revealed that linker length and structure effect inhibition of prion replication in cultured, scrapied cells.
    Type: Application
    Filed: November 25, 2003
    Publication date: November 18, 2004
    Applicant: The Regents of the University of California
    Inventors: Stanley B. Prusiner, Carsten Korth, Barnaby C.H. May
  • Patent number: 6797495
    Abstract: The present invention comprises a method for producing mammalian therapeutics free from prion contamination and cells for use in such methods. Such therapeutics are produced in somatic cells having a genome with an artificially altered PrP gene. The PrP gene in these cells may be ablated, or replaced by an exogenous inducible form of the PrP gene. The endogenous gene in the host cells may be disrupted, or disrupted and replaced by an exogenous PrP gene.
    Type: Grant
    Filed: April 9, 2001
    Date of Patent: September 28, 2004
    Assignee: The Regents of the University of California
    Inventor: Stanley B. Prusiner
  • Patent number: 6767712
    Abstract: The present invention provides a novel PrP protein, and nucleic acids encoding this protein, where the PrP protein is characterized in vivo by 1) incomplete glycosylation relative to glycosylation of wild-type PrPC and 2) proper cellular localization, i.e. an ability to be transported to the cell surface. This novel, under-glycosylated PrP, unlike its normal cellular counterpart, can easily be converted into a protease-resistant isoform by incubation with infectious prions. The invention further provides systems for the study of prion disorders and methods of using these systems, e.g. the study of the mechanical processes in progression of prion-mediated disease or the identification of new therapeutic agents for treatment of prion-mediated disorders. In such systems, protease-resistant under-glycosylated PrP is generated de novo and can be detected by standard immunoblot techniques.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: July 27, 2004
    Assignee: The Regents of the University of California
    Inventors: Stanley B. Prusiner, Carsten Korth